

Nicolas Chapuis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7468785/publications.pdf>

Version: 2024-02-01

64
papers

4,070
citations

218677

26
h-index

144013

57
g-index

64
all docs

64
docs citations

64
times ranked

8084
citing authors

#	ARTICLE	IF	CITATIONS
1	Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues” Recommendations from the European <scp>LeukemiaNet</scp>. <i>Cytometry Part B - Clinical Cytometry</i> , 2023, 104, 15-26.	1.5	16
2	Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European <scp>LeukemiaNet</scp> International <scp>MDS&Flow</scp> Cytometry Working Group. <i>Cytometry Part B - Clinical Cytometry</i> , 2023, 104, 77-86.	1.5	18
3	APR-246 induces early cell death by ferroptosis in acute myeloid leukemia. <i>Haematologica</i> , 2022, 107, 403-416.	3.5	95
4	Etoposide-containing regimens for the treatment of critically ill patients with hematological malignancy-related hemophagocytic lymphohistiocytosis. <i>Acta Oncol&3gica</i> , 2022, 61, 608-610.	1.8	2
5	RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemia. <i>Leukemia</i> , 2022, 36, 1237-1252.	7.2	12
6	Dynamics of circulating calprotectin accurately predict the outcome of moderate COVID-19 patients. <i>EBioMedicine</i> , 2022, 80, 104077.	6.1	7
7	Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications. <i>Diagnostics</i> , 2022, 12, 1659.	2.6	1
8	Lymphocyte Immunophenotyping and CD4/CD8 Ratio in Cerebrospinal Fluid for the Diagnosis of Sarcoidosis-related Uveitis. <i>Ocular Immunology and Inflammation</i> , 2021, 29, 290-298.	1.8	4
9	Venetoclax combination therapy induces deep AML remission with eradication of leukemic stem cells and remodeling of clonal haematopoiesis. <i>Blood Cancer Journal</i> , 2021, 11, 62.	6.2	9
10	ImmunoCluster provides a computational framework for the nonspecialist to profile high-dimensional cytometry data. <i>ELife</i> , 2021, 10, .	6.0	11
11	COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects. <i>Angiogenesis</i> , 2021, 24, 755-788.	7.2	114
12	Oxidative Stress and Inflammatory Biomarkers for the Prediction of Severity and ICU Admission in Unselected Patients Hospitalized with COVID-19. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7462.	4.1	36
13	Asciminib and ponatinib combination in Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 3558-3560.	1.3	12
14	Phenotypic landscape of granulocytes and monocytes by multiparametric flow cytometry: A prospective study of a 1âtube panel strategy for diagnosis and prognosis of patients with MDS. <i>Cytometry Part B - Clinical Cytometry</i> , 2020, 98, 226-237.	1.5	12
15	Paraneoplastic Hyperleukocytosis Mimicking Hematologic Malignancy Revealing a Localized Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2020, 109, e203-e206.	1.3	1
16	Pairing MCLâ1 inhibition with venetoclax improves therapeutic efficiency of BH3âmimetics in AML. <i>European Journal of Haematology</i> , 2020, 105, 588-596.	2.2	38
17	Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19. <i>Cell</i> , 2020, 182, 1401-1418.e18.	28.9	663
18	Antileukemic activity of the VPS34-IN1 inhibitor in acute myeloid leukemia. <i>Oncogenesis</i> , 2020, 9, 94.	4.9	23

#	ARTICLE	IF	CITATIONS
19	MulticentricMFI30study: Standardization of flow cytometry analysis ofCD30expression innonâ€Hodgkinlymphoma. Cytometry Part B - Clinical Cytometry, 2020, 100, 488-496.	1.5	4
20	A meal served cold. British Journal of Haematology, 2020, 190, 12-12.	2.5	1
21	Rationale for Targeting Deregulated Metabolic Pathways as a Therapeutic Strategy in Acute Myeloid Leukemia. Frontiers in Oncology, 2019, 9, 405.	2.8	29
22	The fraction of CD117/câ€KITâ€expressing erythroid precursors predicts ESA response in lowâ€risk myelodysplastic syndromes. Cytometry Part B - Clinical Cytometry, 2019, 96, 215-222.	1.5	10
23	Too big for flow. Blood, 2019, 134, 576-576.	1.4	3
24	CD13 expression in B cell malignancies is a hallmark of plasmacytic differentiation. British Journal of Haematology, 2019, 184, 625-633.	2.5	10
25	Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes. Haematologica, 2019, 104, 497-504.	3.5	17
26	A pernicious mean corpuscular volume. Blood, 2018, 131, 472-472.	1.4	0
27	Multicenter validation of the flow measurement of classical monocyte fraction for chronic myelomonocytic leukemia diagnosis. Blood Cancer Journal, 2018, 8, 114.	6.2	16
28	A miR-150/TET3 pathway regulates the generation of mouse and human non-classical monocyte subset. Nature Communications, 2018, 9, 5455.	12.8	33
29	Revising flow cytometric mini-panel for diagnosing low-grade myelodysplastic syndromes: Introducing a parameter quantifying CD33 expression on CD34+ cells. Leukemia Research, 2018, 71, 75-81.	0.8	11
30	Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes. Blood, 2017, 129, 484-496.	1.4	22
31	Plasma cell leukemia revealing a G6PD deficiency. Blood, 2016, 128, 3178-3178.	1.4	2
32	Cytoplasmic proliferating cell nuclear antigen connects glycolysis and cell survival in acute myeloid leukemia. Scientific Reports, 2016, 6, 35561.	3.3	47
33	Immature/total granulocyte ratio improves early prediction of neurological outcome after out-of-hospital cardiac arrest: the MyeloScore study. Annals of Intensive Care, 2016, 6, 65.	4.6	10
34	Plasma vemurafenib exposure and pre-treatment hepatocyte growth factor level are two factors contributing to the early peripheral lymphocytes depletion in BRAF-mutated melanoma patients. Pharmacological Research, 2016, 113, 709-718.	7.1	6
35	Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells. Oncotarget, 2016, 7, 35753-35767.	1.8	46
36	APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesis. Oncotarget, 2016, 7, 14898-14911.	1.8	11

#	ARTICLE	IF	CITATIONS
37	Clonal B-Cell Lymphocytosis with Marginal Zone Features and Splenic Marginal Zone Lymphoma Share a Similar Cytogenetic and Mutational Profile. <i>Blood</i> , 2016, 128, 2962-2962.	1.4	0
38	Architectural and Functional Heterogeneity of Hematopoietic Stem/Progenitor Cells in Non-Del(5q) Myelodysplastic Syndromes. <i>Blood</i> , 2016, 128, 3153-3153.	1.4	0
39	Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition. <i>Blood</i> , 2015, 126, 1346-1356.	1.4	303
40	Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric Ogata score in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. <i>Haematologica</i> , 2015, 100, 472-478.	3.5	28
41	Comparison of cross-platform flow cytometry minimal residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategy. , 2015, 88, 101-109.		9
42	Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parameters. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 1033-1039.	2.3	7
43	Pegylated liposomal doxorubicin-induced palmar plantar erythrodysesthesia: Identification of risks factors.. <i>Journal of Clinical Oncology</i> , 2015, 33, e13569-e13569.	1.6	0
44	Sustained Leukemia-Free State and Molecular Response to Sorafenib in a Patient With Chronic Myelomonocytic Leukemia in Transformation Driven by Homozygous FLT3-ITD Malignant Hematopoiesis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 347-350.	0.4	3
45	Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia. <i>Blood</i> , 2013, 122, 3521-3532.	1.4	240
46	A dramatic fetal outcome following transplacental transfer of dasatinib. <i>Anti-Cancer Drugs</i> , 2012, 23, 754-757.	1.4	44
47	PI3K and mTOR Signaling Pathways in Cancer: New Data on Targeted Therapies. <i>Current Oncology Reports</i> , 2012, 14, 129-138.	4.0	175
48	Salvage therapy of Autoimmune Thrombocytopenic Purpura revealing non-Hodgkin Lymphoma by the thrombopoietin receptor agonist romiplostim. <i>British Journal of Haematology</i> , 2012, 156, 145-147.	2.5	7
49	The eukaryotic Initiating Factor 4E protein is overexpressed, but its level has no prognostic impact in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2012, 156, 547-550.	2.5	5
50	High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study. <i>Haematologica</i> , 2011, 96, 1792-1798.	3.5	164
51	LKB1/AMPK/mTOR signaling pathway in hematological malignancies: From metabolism to cancer cell biology. <i>Cell Cycle</i> , 2011, 10, 2115-2120.	2.6	94
52	Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody. <i>Haematologica</i> , 2010, 95, 415-423.	3.5	129
53	Î²B kinase overcomes PI3K/Akt and ERK/MAPK to control FOXO3a activity in acute myeloid leukemia. <i>Blood</i> , 2010, 116, 4240-4250.	1.4	69
54	The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation. <i>Blood</i> , 2010, 116, 4262-4273.	1.4	173

#	ARTICLE	IF	CITATIONS
55	Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies. <i>Leukemia</i> , 2010, 24, 1686-1699.	7.2	100
56	Insulin Receptor A and IGF-1R in AML – Letter. <i>Cancer Research</i> , 2010, 70, 7010.1-7010.	0.9	6
57	Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2010, 16, 5424-5435.	7.0	146
58	Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. <i>Haematologica</i> , 2010, 95, 819-828.	3.5	240
59	Targeting translation in acute myeloid leukemia: A new paradigm for therapy?. <i>Cell Cycle</i> , 2009, 8, 3893-3899.	2.6	51
60	Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. <i>Blood</i> , 2009, 114, 1618-1627.	1.4	169
61	PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. <i>Leukemia</i> , 2008, 22, 1698-1706.	7.2	170
62	Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapy. <i>Leukemia and Lymphoma</i> , 2008, 49, 2012-2014.	1.3	23
63	Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. <i>Blood</i> , 2008, 111, 379-382.	1.4	234
64	Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. <i>Blood</i> , 2007, 110, 1025-1028.	1.4	129